Search the Video Library

Filter by Date

Video Language

Filter by Cancer Type:

Displaying Results 91 - 94 of 94

Managing Three Compartments in Stage III Disease (Local, Distant, CNS)

Dr. Mark Socinski, University of Pittsburgh Medical Center, defines the three compartments in stage III (locally advanced) NSCLC, each of which must be treated.

Heterogeneity of Stage III NSCLC/Defining Resectability for Locally Advanced NSCLC

Dr. Mark Socinski, University of Pittsburgh Medical Center, describes the different types of stage III (locally advanced) NSCLC, and states which of these types tend to be resectable.

High vs. Standard Dose Chest Radiation in Stage III Lung Cancer

Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, provides trial evidence showing that patients may not benefit from high dose chest radiation therapy vs. standard dose therapy.

Spanish Blood Cancer Library - What are the risks and benefits of Ibrutinib and Idelalisib? How do you manage the side effects of the new kinase inhibitors?
¿Cuáles son los riesgos y beneficios de ibrutinib y de idelalisib? ¿Cómo manejamos los efectos secundarios de los nuevos inhibidores de la tirosina cinasa?

GRACE sat down with Dr. Marco Ruiz to discuss "What are the risks and benefits of Ibrutinib and Idelalisib?" for our continuing video series with our Spanish speaking faculty on updates in blood cancer treatments.